Author: angelinneed

During the opening session of the AACR Conference on Drug Discovery and Development, the conference cochairs—Patricia M. LoRusso, DO, PhD (hc), FAACR; Keith T. Flaherty MD, FAACR; Lillian L. Siu, MD, FAACR; and Timothy A. Yap, MBBS, PhD—led a panel discussion with leading voices from industry and venture capital, including Alexis Borisy, MS, cofounder and chairman of the venture capital firm Curie.Bio; Chris Boshoff, MD, PhD, chief scientific officer and president of research and development at Pfizer; and David Schenkein, MD, general partner of the venture capital firm Google Ventures.

The post Inaugural AACR D3 Opens With Insights From Leaders Across Drug Discovery and Development appeared first on American Association for Cancer Research (AACR).

At the recent AACR Special Conference on Breaking Barriers in the Fight Against Rare Cancers, AACR Immediate Past President Lillian L. Siu, MD, FAACR, announced the AACR Rare Cancers Initiative. Learn more about how this new Initiative will marshal global resources and expertise to drive rare cancer research forward.

The post The AACR Rare Cancers Initiative: Uniting Researchers, Undoing Barriers, and Unleashing Progress appeared first on American Association for Cancer Research (AACR).

Cancer immunology expert and former AACR president Elizabeth Jaffee, MD, FAACR, discusses the latest progress in the research on pancreatic cancer vaccines and explains why cancer interception in individuals at high risk is the new frontier of the field.

The post From Treatment to Prevention: How Vaccines Are Reshaping the Fight Against Pancreatic Cancer appeared first on American Association for Cancer Research (AACR).

Exposure to wildfire smoke may increase the risk of developing several cancers, according to research presented at the AACR Annual Meeting 2026 by Shuguang Leng, MBBS, PhD, and Qizhen Wu, PhD, both of the University of New Mexico Comprehensive Cancer Center. Amid bigger U.S. wildfires, wildfire smoke’s impacts on human health are increasingly relevant.

The post Catching the Drift: How Wildfire Smoke Plumes May Increase Cancer Risk appeared first on American Association for Cancer Research (AACR).

Cancer researchers—including Elizabeth M. Jaffee, MD, FAACR, of the Sidney Kimmel Cancer Center at Johns Hopkins; Robert H. Vonderheide, MD, DPhil, FAACR, of the Abramson Cancer Center of the University of Pennsylvania; Kornelia Polyak, MD, PhD, FAACR, of Dana-Farber Cancer Institute and Harvard Medical School; Cornelia Ulrich, PhD, of the Huntsman Cancer Institute and University of Utah; Electra D. Paskett, PhD, FAACR, of The Ohio State University, and Anna Barker, PhD, FAACR, of the Ellison Medical Institute—explain how certain provisions of the White House Office of Management and Budget’s proposal to change how federal grants are awarded and managed would be harmful to U.S. scientific and medical innovation.

The post Cancer Researchers Explain How OMB’s Proposed Changes to Federal Grantmaking Will Cause Delays, Reduce Transparency, and Undermine Merit-based Processes appeared first on American Association for Cancer Research (AACR).

After surviving brain cancer, former competitive cyclist Chris Baccash dedicated his life to helping others. Baccash now uses his passion for cycling to make an impact, including by participating in the upcoming Philadelphia Cycling Classic Charity Ride for AACR.

The post Chris Baccash: A Brain Cancer Survivor Who Is Cycling to Make a Difference appeared first on American Association for Cancer Research (AACR).

At the AACR Special Conference on Advances in Malignant Lymphoma, Ronald Levy, MD, FAACR, of Stanford University, discussed how monoclonal antibodies transformed lymphoma treatment; Michel C. Nussenzweig, MD, PhD, of The Rockefeller University, explored affinity and diversity in the antibody response; and conference chair Michael Green, PhD, of The University of Texas MD Anderson Cancer Center, examined epigenetic mechanisms that affect response to targeted therapy.

The post From Discovery to Clinical Impact: AACR Special Conference Captured the Spectrum of Lymphoma Research appeared first on American Association for Cancer Research (AACR).

During the second quarter of 2026, oncology approvals issued by the U.S. Food and Drug Administration expanded the treatment options available for patients with breast cancer, urinary cancers, prostate cancer, rare cancers, and hematologic malignancies. Learn about each new approval and how it fits into the therapeutic landscape.

The post FDA Approvals in Oncology: April-June 2026  appeared first on American Association for Cancer Research (AACR).

The June edition of Editors’ Picks from the AACR journals included studies on targeting neural cross-talk to stop glioblastoma recurrence, identifying patients with multiple myeloma who may benefit from debulking chemotherapy, examining considerable improvements between 1975 and 2020 in survival rates of childhood and adolescent cancer patients, and much more.

The post Editors’ Picks, June 2026: Preventing Colorectal Cancer, Targeting Neural Cross-talk to Stop Glioblastoma Recurrence, and More appeared first on American Association for Cancer Research (AACR).

At the AACR Annual Meeting 2026, a session highlighted progress from four Cancer Grand Challenges teams on the interplay of mutations, promoting factors, and tissue-specific epigenetic programs in cancer development and on the biology of cachexia. Speakers included Michael R. Stratton, MBBS, PhD, FAACR, of the Wellcome Sanger Institute; Allan Balmain, PhD, FAACR, of the University of California, San Francisco; Karen M. Cichowski, PhD, of Harvard Medical School; and Eileen White, PhD, FAACR, of Rutgers University.

The post At the AACR Annual Meeting 2026, Cancer Grand Challenges Teams Explore How Cancer Forms and Evolves appeared first on American Association for Cancer Research (AACR).